Evaluation of Skin Penetration of Diclofenac from a Novel Topical Non Aqueous Solution: A Comparative Bioavailability Study

MANISH NIVSARKAR1, SANJAYKUMAR H. MAROO2, KETAN R. PATEL3, DIXIT D. PATEL4

ABSTRACT

Introduction: Different topical formulations of diclofenac have varying skin penetration profile. Recent advances in science and technology has led to the development of many new formulations of drugs for topical drug delivery. One such technological development has led to the innovation of Dynapar QPS, a novel, non-aqueous, quick penetrating solution (QPS) of diclofenac diethylamine.

Aim: This study was aimed to measure the total exposure from the drug penetrating the skin in healthy human subjects and comparing the relative systemic bioavailability of Dynapar QPS with diclofenac emulgel.

Materials and Methods: A 200 mg of diclofenac from either Dynapar QPS (5 ml) or emulgel (20 g) was applied on back of subject as per the randomisation schedule. Blood samples were collected up to 16 hours post drug application. Plasma concentration of diclofenac was measured by pre-validated HPLC method. Pharmacokinetic (PK) parameters like $C_{max}$, $T_{max}$, $t_{1/2}$, AUC$_{0-t}$, AUC$_{0-\infty}$, and $K_{e}$ of diclofenac were determined for both the formulations.

Results: Mean $C_{max}$ after administration of Dynapar QPS and diclofenac emulgel were 175.93 and 40.04 ng/ml, respectively. $T_{max}$ of diclofenac was almost half with QPS compared to emulgel (5.24 hrs versus 9.53 hrs respectively). The mean AUC$_{0-t}$ and AUC$_{0-\infty}$ after administration of Dynapar QPS was higher as compared to diclofenac emulgel (AUC$_{0-t}$: 1224.19 versus 289.78 ng.h/ml, respectively; AUC$_{0-\infty}$: 1718.21 versus 513.83 ng.h/ml, respectively). None of the subject experienced any adverse event during the study.

Conclusion: The results indicate an enhanced penetration and subsequent absorption of diclofenac from Dynapar QPS as compared to diclofenac emulgel. Higher penetration is likely to translate into better pain relief in patients.

INTRODUCTION

Skin, the largest organ, is a formidable barrier to the passage of substances into and out of the body. Skin is composed of three primary layers, the outer epidermis, middle dermis and the hypodermis. The epidermis consists of multiple strata (layers). Stratum corneum, the outermost layer of the skin, is where all of the skin’s barrier property resides. It functions as a physical, environmental and microbial barrier, protecting from external insult and maintaining homeostasis. In order to use the skin as a route for topical drug delivery, this barrier must be overcome. Ideal characteristics of a drug to efficiently penetrate the skin is that the drug molecule should be small in size (<500 Daltons) [1], relatively neutral and lipophilic in nature. A limitation of commonly available topical formulations of drugs is their inability to effectively penetrate the barrier of stratum corneum.

Several studies have reported that, diclofenac is a good NSAID candidate for topical formulations [2]. Diclofenac is the first NSAID approved for topical use in osteoarthritis therapy [3]. Diclofenac is an extensively used NSAID with strong analgesic effect. It is a small molecule (molecular weight of 296.14 Dalton) having a short half-life of 2 hours. Theoretically, this makes diclofenac a suitable molecule for topical formulations. But in clinical practice, transdermal penetration of diclofenac has been found to be variable [4,5]. Only 10% of diclofenac from currently available topical formulations is biologically available [6]. Christopher et al., reported that even nano-particulate based, topical drug delivery systems, cannot penetrate beyond the superficial layers of the barrier [7]. Several strategies have been employed to overcome the problem of low permeability through the skin [8,9]. A popular approach is to use penetration enhancers. These agents partition into the skin, and interact with the constituents of stratum corneum to induce a temporary, reversible increase in skin permeability [10]. An advanced topical formulation with efficient penetration enhancers can make a huge difference in skin permeation of drug molecules.

Dynapar QPS, manufactured by Troikaa Pharmaceuticals Ltd, India, is a novel, non-aqueous, topical formulation of diclofenac diethylamine solubilised in a patented QPS base, which provides quick and comprehensive penetration of drug through the skin. The QPS is a patented technology providing a platform for enhanced penetration of drug into the deeper tissues. Since this novel formulation provides significantly higher transdermal penetration, it quickly relieves musculoskeletal pain and reduce inflammation [11]. A diclofenac formulation with a high degree of skin permeation could be useful in the treatment of inflammatory and painful musculoskeletal conditions.

Higher systemic bioavailability can be correlated with the extent of skin penetration of diclofenac from novel formulation. To evaluate the skin permeation of this novel topical formulation, the plasma levels of diclofenac achieved from Dynapar QPS and Diclofenac gel were estimated. Several methods have been reported for determination of diclofenac including gas chromatography-mass spectrometry (GC–MS), high-performance liquid chromatography (HPLC) and LC–MS–MS in human plasma and other biological fluids [12].

In the present study, we have used a simple HPLC with UV method for determination of diclofenac in human plasma. The developed...
Subjects were housed in the clinical facility 10 hrs before bioavailability study. This was an open label, balanced, randomized, two-treatment, reference drug. Solution 4%; Troikaa pharmaceuticals Ltd., India) was used as test Dynapar QPS Thaltej, Ahmedabad, Gujarat, India. The study was conducted during December 2010 to January 2011 at B. V. Patel PERD Centre, Sarkhej-Gandhinagar Highway, Ahmedabad, Gujarat, India. Subjects were healthy, non-smoking, adult male volunteers (mean age±SD, 32.70±5.64) were enrolled in the study based on normal findings from laboratory investigations. The mean Body Mass Index (BMI) of the subjects was 22.49 ± 1.93 kg/m². The study protocol was approved by the Institutional Ethics Committee and the study was conducted in accordance with Good Clinical Practice (GCP) and the Declaration of Helsinki. Prior to any screening procedure, written consent was obtained from each subject participating in this study after adequate explanation of the aims, methods, objective, and potential hazards of the study.

Main exclusion criteria were: hypersensitivity to any allergens, history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or any other systemic disease; regular alcohol intake or drug abuse within the past one-year; smoking (more than 10 cigarettes per day) or consumption of tobacco products. The volunteers were asked to abstain from taking any medication, all type of tobacco products and alcohol, throughout the study period.

The study was conducted during December 2010 to January 2011 at B. V. Patel PERD Centre, Sarkhej-Gandhinagar Highway, Thaltej, Ahmedabad, Gujarat, India.

Study Drugs
Dynapar QPS® (Diclofenac diethylamine non-aqueous topical solution 4%; Troikaa pharmaceuticals Ltd., India) was used as test and Emulgel 1% (diclofenac sodium emulgel 1%) was used as reference drug.

Study Design
This was an open label, balanced, randomized, two-treatment, two-sequence, two-period, single dose, crossover comparative bioavailability study.

Subjects were housed in the clinical facility 10 hrs before administration of the dose and were discharged 24 hours post dose. As per the randomisation sheet, 200 mg of diclofenac from either diclofenac QPS (5 ml) or emulgel (20 g) was applied on the back of each subject. The wash-out time between period I and period II of the study was 7 days. Subjects were kept in prone position for 2 hours and were not allowed to wear their shirt till 4 hours.

All subjects received standard light breakfast one hour prior to dosing; and lunch, snacks (fruit juice and biscuits) and dinner 4, 8 and 12 hours post dosing. During housing, all meal plans were similar for both the periods.

Blood Sampling
Blood samples (6 ml aliquots including 0.2 ml discarded heparinised blood) were collected in labeled vacuumtubes before dosing and at 15, 30, 45 minutes, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 16 hours after dosing. Centrifugation of blood samples was carried out at 4°C and 4000 rpm for 7 minutes to separate plasma. Plasma samples were stored in deep freezer at ~20 ± 5°C for interim storage and finally stored at ~70 ± 5°C until analysed.

Determination of Diclofenac in Human Plasma Sample preparation
Samples were prepared by vortex mixing 50 μl Mafenamic Acid (internal standard) to 500 μl plasma, followed by addition of 50 μl of 6% trichloroanisole (TCA). This was again vortex mixed briefly and extracted with 6ml Dichloromethane. The organic fraction was separated, evaporated and reconstituted in 100 μl mobile phase. A 70μl aliquot of this extract was injected onto HPLC column.

HPLC Conditions and Sample Analysis
Analytes were separated using a reverse phase Grace Vydac C18 (250 x 4.6 mm, 5 micron) analytical column and the UV detector set at 282 nm. Auto sampler temperature was ambient. The mobile phase consisted of 65 % (v/v) buffer 10 mM potassium di hydrogen orthophosphate in water, pH 6.30 adjusted with dilute potassium hydroxide solution,) and 35% acetonitrile. The flow rate was 0.8 ml.min⁻¹. The lower limit of quantification of diclofenac was 5 ng.ml⁻¹. The intra and interday precision and accuracy for low (20 ng/ml), medium (400 ng/ml) and high (850 ng/ml) concentrations of diclofenac were < 15% and < 20% (at lowest limit of quantification).

Pharmacokinetic Analysis
The maximum plasma concentration (Cmax) and the time to reach Cmax (Tmax) were determined for individual plasma concentration time profiles. The slope of the terminal log-linear portion of the concentration-time profile was determined by least-squares regression analysis and used for estimation of elimination rate constant (Kel). The terminal half life (t1/2) was calculated by the formula 0.693/Kel. The AUC(0-t) from time zero to the last quantifiable point (Ct) was calculated using the trapezoidal rule and the extrapolated AUC from Ct to infinity AUC(0-∞) was determined as C/t1/2. The area under the plasma concentration-time from zero to infinity AUC(0-∞) was calculated as the sum of the AUC(0-t) and the ratio of the last measurable concentration to the elimination rate constant.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Cmax (ng/ml)</th>
<th>Tmax (hrs)</th>
<th>AUC(0-t) (ng.h/ml)</th>
<th>AUC(0-∞) (ng.h/ml)</th>
<th>t1/2 (hrs)</th>
<th>Kel (h⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEAN</td>
<td>175.93</td>
<td>40.04</td>
<td>5.24</td>
<td>9.53</td>
<td>1224.19</td>
<td>289.78</td>
</tr>
<tr>
<td>SD</td>
<td>89.49</td>
<td>26.62</td>
<td>2.59</td>
<td>4.2</td>
<td>445.69</td>
<td>139.74</td>
</tr>
<tr>
<td>SEM</td>
<td>20.53</td>
<td>6.11</td>
<td>0.59</td>
<td>0.96</td>
<td>102.25</td>
<td>32.06</td>
</tr>
<tr>
<td>N</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
<td>17</td>
</tr>
<tr>
<td>% CV</td>
<td>50.9</td>
<td>66.5</td>
<td>49.4</td>
<td>44.1</td>
<td>36.4</td>
<td>48.2</td>
</tr>
<tr>
<td>p-value</td>
<td>0.0001</td>
<td>0.0011</td>
<td>0.0001</td>
<td>0.0001</td>
<td>0.3498</td>
<td>0.7044</td>
</tr>
</tbody>
</table>

[Table/Fig-1]: Summary of pharmacokinetic parameters of diclofenac diethylamine in plasma, following administration of the reference and test formulations: R: Reference formulation (emulgel); T: Test formulation (QPS); Data were analysed by unpaired t-test.
Higher AUC values indicate a trend towards 4 folds higher bioavailability from Dynapar QPS as compared to gel. The higher penetration of Dynapar QPS as expressed by the comparative bioavailability study, establishes that advanced formulation of Dynapar QPS would provide more efficient and deeper skin penetration and provide early onset of clinical benefits. Further studies are recommended to measure plasma as well as tissue concentrations after oral administration and topical diclofenac application.

CONCLUSION

In this comparative bioavailability study, the rate and extent of diclofenac penetration from skin was higher from Dynapar QPS and thus has higher bioavailability as compared to diclofenac emulgel formulation. This higher topical bioavailability may translate into clinical superiority of Dynapar QPS over emulgel.

ACKNOWLEDGEMENT

This study was sponsored by Troikaa Pharmaceuticals Ltd., India. Authors would like to thank all the study subjects for their valuable participation and study team members for their dedication work in this study.

REFERENCES